Evidence map›Paper›PMID 35998194›Full record

ArticlePloS one2022

Plant-derived compounds effectively inhibit the main protease of SARS-CoV-2: An in silico approach.

Shafi Mahmud, Shamima Afrose, Suvro Biswas, Abir Nagata, Gobindo Kumar Paul, Mohasana Akter Mita, Md Robiul Hasan, Mst Sharmin Sultana Shimu, Shahriar Zaman, Md Salah Uddin and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Drugs against broad-spectrum of coronaviruses.Frontiers in immunology · 2026
    Review
  2. Article
  3. Article
  4. Metabolites · 2024
    Article
  5. Article
  6. Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Preliminary Evaluation ofACS omega · 2023
    Article
  11. Article
  12. In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors fromAdvances and applications in bioinformatics and chemistry : AABC · 2023
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Shafi MahmudDivision of Genome Sciences and Cancer, The John Curtin School of Medical Research, and The Shine-Dalgarno Centre for RNA Innovation, The Australian National University, Canberra, Australian Capital Territory, Australia.
Shamima AfroseDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Suvro BiswasMicrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Abir NagataDepartment of Regenerative Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-6151-5732
Gobindo Kumar PaulMicrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mohasana Akter MitaDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Robiul HasanDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mst Sharmin Sultana ShimuDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shahriar ZamanMicrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Salah UddinMicrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Sayeedul IslamDepartment of Biological Sciences, Graduate School of Science, Osaka University, Toyonaka, Osaka, Japan.
Md Abu SalehMicrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.ORCID 0000-0001-5610-4763
University of Rajshahi · BDThe University of Osaka · JPAustralian National University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current coronavirus disease 2019 (COVID-19) pandemic, caused by the coronavirus 2 (SARS-CoV-2), involves severe acute respiratory syndrome and poses unprecedented challenges to global health. Structure-based drug design techniques have been developed targeting the main protease of the SARS-CoV-2, responsible for viral replication and transcription, to rapidly identify effective inhibitors and therapeutic targets. Herein, we constructed a phytochemical dataset of 1154 compounds using deep literature mining and explored their potential to bind with and inhibit the main protease of SARS-CoV-2. The three most effective phytochemicals Cosmosiine, Pelargonidin-3-O-glucoside, and Cleomiscosin A had binding energies of -8.4, -8.4, and -8.2 kcal/mol, respectively, in the docking analysis. These molecules could bind to Gln189, Glu166, Cys145, His41, and Met165 residues on the active site of the targeted protein, leading to specific inhibition. The pharmacological characteristics and toxicity of these compounds, examined using absorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses, revealed no carcinogenicity or toxicity. Furthermore, the complexes were simulated with molecular dynamics for 100 ns to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen profiles from the simulation trajectories. Our analysis validated the rigidity of the docked protein-ligand. Taken together, our computational study findings might help develop potential drugs to combat the main protease of the SARS-CoV-2 and help alleviate the severity of the pandemic.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Coronavirus 3C ProteasesEndopeptidasesHumansMolecular Docking SimulationMolecular Dynamics SimulationPandemicsPeptide HydrolasesProtease InhibitorsCoronavirus 3C ProteasesEndopeptidasesPeptide HydrolasesProtease Inhibitors

Identifiers

PMID35998194
PMCPMC9398018
OpenAlexW4292767227

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.